About Aptose Biosciences
Aptose Biosciences is a company based in Mississauga (Canada) founded in 1986 was acquired by Hanmi Pharmaceuticals in November 2025. It operates as a HealthTech. The company has 13 employees as of December 31, 2024. Aptose Biosciences offers products and services including Tuspetinib, Luxeptinib (B-NHL), and Luxeptinib (AML/MDS).
- Headquarter Mississauga, Canada
- Employees 13 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aptose Biosciences. Inc.
-
Annual Revenue
Not available
-
Net Profit
-$24.21 M (USD)53.57as on Dec 31, 2024
-
EBITDA
-$24.61 M (USD)53.42as on Dec 31, 2024
-
Latest Funding Round
$9.7 M (USD), Post-IPO
Jan 31, 2024
- Investors
-
Employee Count
13
as on Dec 31, 2024
-
Acquired by
Hanmi Pharmaceuticals
(Nov 19, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Aptose Biosciences
Aptose Biosciences is a publicly listed company on the OTC with ticker symbol APTOF in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Aptose Biosciences
Aptose Biosciences offers a comprehensive portfolio of products and services, including Tuspetinib, Luxeptinib (B-NHL), and Luxeptinib (AML/MDS).
Tuspetinib is developed for treating myeloid malignancies like AML.
Luxeptinib is formulated for B-cell malignancies including CLL, NHL.
Luxeptinib targets myeloid malignancies such as AML and MDS.
People of Aptose Biosciences
Unlock access to complete
Funding Insights of Aptose Biosciences
Investors in Aptose Biosciences
Aptose Biosciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Hanmi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
NCEs and generic pharmaceutical products are developed and manufactured.
|
Locked | Locked | Locked |
Investor details for Aptose Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aptose Biosciences
Investment portfolio details for Aptose Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aptose Biosciences
Detailed financials for Aptose Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aptose Biosciences Comparisons
Peer comparison for Aptose Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aptose Biosciences
Detailed competitors of Aptose Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aptose Biosciences
Complete news archive for Aptose Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aptose Biosciences
Aptose Biosciences was founded in 1986 and raised its 1st funding round 26 years after it was founded.
Aptose Biosciences is headquartered in Mississauga, Canada. It is registered at Mississauga, Ontario, Canada.
As of Dec 31, 2024, the latest employee count at Aptose Biosciences is 13.
Aptose Biosciences is engaged in developing precision medicines for oncology, with a primary focus on hematology. The company is involved in creating small molecule cancer therapeutics designed for single agent efficacy and to complement other anti-cancer therapies without overlapping toxicities. Their pipeline includes products targeting myeloid and lymphoid malignancies such as AML, CLL, NHL, and MDS. Clinical trials are conducted to address unmet needs in these areas, covering multiple indications within the hematology spectrum.
Aptose Biosciences offers Tuspetinib, Luxeptinib (B-NHL), and Luxeptinib (AML/MDS).
Yes, Aptose Biosciences is publicly traded on OTC under the ticker symbol APTOF.
Aptose Biosciences has 1 investor. Key investors include Hanmi.
The ticker symbol of Aptose Biosciences is APTOF on OTC.